Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

5.32
-0.0800-1.48%
Post-market: 5.30-0.0200-0.38%19:57 EDT
Volume:8.19M
Turnover:42.51M
Market Cap:458.65M
PE:-1.41
High:5.50
Open:5.48
Low:4.98
Close:5.40
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:64.06M
Volume Ratio:0.47
T/O Rate:12.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.76
PE(LYR):-1.68

Loading ...

EyePoint Grants Inducement Stock Options for 14,600 Shares at $14.75 Each

Reuters
·
Aug 15

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 15

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Simply Wall St.
·
Aug 14

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

EyePoint (EYPT) Completes Phase 3 Enrollment Early, Is The Stock Still Cheap?

Simply Wall St.
·
Aug 10

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 07

Smart Glass Tech Developer Research Frontiers' Q2 Fee Income Declines

Reuters
·
Aug 07

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

UK's Immunocore Q2 EPS Misses Estimates

Reuters
·
Aug 06

EyePoint is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 06

EyePoint price target lowered to $27 from $30 at H.C. Wainwright

TIPRANKS
·
Aug 06

Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile

TIPRANKS
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Aug 06

EyePoint Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss

TradingKey
·
Aug 05

EyePoint reports Q2 EPS ($1.09), consensus (96c)

TIPRANKS
·
Aug 05

EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate

Benzinga Earnings
·
Aug 05